AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19047026 — intervention group
Group type: EXPERIMENTAL
Intervention: AUDIT-C group (moderate alcohol misuse)
Number of subjects: 13470
Study 19047026 — intervention group
Group type: COMPARATOR
Intervention: Oral hypoglycemics
Number of subjects: 13470
Study 17156625 — intervention group
Group type: EXPERIMENTAL
Intervention: T(3) sympathectomy
Number of subjects: 106
Study 17156625 — intervention group
Group type: EXPERIMENTAL
Intervention: T(4) sympathectomy
Number of subjects: 106
Study 12767415 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxicillin/clavulanate
Number of subjects: 251
Study 12767415 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 251
Study 11323338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 180
Study 11323338 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 180
Study 8995350 — intervention group
Group type: EXPERIMENTAL
Intervention: Dios (Daflon 500 mg)
Number of subjects: 104
Study 8995350 — intervention group
Group type: COMPARATOR
Intervention: Plac (placebo)
Number of subjects: 104
Study 8127216 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium w vaccine (initial dose)
Number of subjects: 307981
Study 8127216 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium w vaccine (booster dose)
Number of subjects: 307981
Study 8127216 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initial dose)
Number of subjects: 307981
Study 8127216 — intervention group
Group type: COMPARATOR
Intervention: Placebo (booster dose)
Number of subjects: 307981
Study 3306131 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandwich chemotherapy (administered between surgery and postoperative irradiation)
Number of subjects: 0
Study 3306131 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with CCNU and vincristine
Number of subjects: 0
Study 3306131 — intervention group
Group type: COMPARATOR
Intervention: Sandwich chemotherapy (as administered)
Number of subjects: 0
Study 3306131 — intervention group
Group type: COMPARATOR
Intervention: Reduced radiotherapy doses to the supratentorial area and to the spine in low risk patients
Number of subjects: 0
Study 3306131 — intervention group
Group type: COMPARATOR
Intervention: Classical risk factors
Number of subjects: 0
Study 2397975 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electrical field treatment administered over 36 weeks
Number of subjects: 30
Study 2397975 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 30
Study 4922754 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 15 mg daily
Number of subjects: 51
Study 4922754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 31228771 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular screening for CAD using noninvasive tests prior to wait-listing and annually after wait-listing until transplantation.
Number of subjects: 3306
Study 31228771 — intervention group
Group type: COMPARATOR
Intervention: Eliminating screening tests for occult CAD after wait-listing.
Number of subjects: 3306
Study 31228771 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular screening for CAD.
Number of subjects: 3306
Study 28108790 — intervention group
Group type: EXPERIMENTAL
Intervention: Apnea Sleep Position Trainer (Android) and SomnoPose‐Sleep Position Monitor (iOS)
Number of subjects: 33
Study 28108790 — intervention group
Group type: COMPARATOR
Intervention: Control polysomnography (PSG) after 1 month
Number of subjects: 33
Study 26145272 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct exposure to 33% fat-reduced variant
Number of subjects: 219
Study 26145272 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct exposure to 28% sugar-reduced variant
Number of subjects: 219
Study 26145272 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard variant)
Number of subjects: 219
Study 26145272 — intervention group
Group type: COMPARATOR
Intervention: Stepwise exposure (more reduced variants)
Number of subjects: 219
Study 23459887 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits and phone calls (4 home visits and 4 phone calls over 6 months)
Number of subjects: 200
Study 23459887 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow up with no visits or phone calls
Number of subjects: 200
Study 21164355 — intervention group
Group type: EXPERIMENTAL
Intervention: hApoA-I overexpression via intraportal/vector administration
Number of subjects: 0
Study 21164355 — intervention group
Group type: EXPERIMENTAL
Intervention: hApoA-I overexpression via intramuscular/vector administration
Number of subjects: 0
Study 21164355 — intervention group
Group type: COMPARATOR
Intervention: hApoA-I overexpression (both routes)
Number of subjects: 0
Study 19111806 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy, chemotherapy, or a combination
Number of subjects: 0
Study 19111806 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 0
Study 17910225 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive patch applied to Class II cavities
Number of subjects: 20
Study 17910225 — intervention group
Group type: COMPARATOR
Intervention: Control group (fillings without patch application)
Number of subjects: 20
Study 12825024 — intervention group
Group type: EXPERIMENTAL
Intervention: International collaborative research working group
Number of subjects: 29
Study 12825024 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative projects
Number of subjects: 29
Study 10376122 — intervention group
Group type: EXPERIMENTAL
Intervention: D-fenfluramine (30 mg p.o.)
Number of subjects: 32
Study 10376122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 8917239 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of lidocaine/prilocaine (EMLA) cream
Number of subjects: 40
Study 8917239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1785238 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 44
Study 1785238 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 44
Study 6355269 — intervention group
Group type: EXPERIMENTAL
Intervention: C.B.S. tablets (1 four times daily)
Number of subjects: 51
Study 6355269 — intervention group
Group type: EXPERIMENTAL
Intervention: C.B.S. liquid (5 ml four times daily)
Number of subjects: 51
Study 6355269 — intervention group
Group type: COMPARATOR
Intervention: C.B.S. tablets and liquid
Number of subjects: 51
Study 30933856 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 5000
Study 30933856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5000
Study 28862100 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopy‐assisted intramedullary nailing (AIMN); n = 20
Number of subjects: 40
Study 28862100 — intervention group
Group type: COMPARATOR
Intervention: Conventional intramedullary nailing (IMN); n = 20
Number of subjects: 40
Study 25218879 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-taste sensory activity program (looking, listening, feeling, and smelling activities with unusual fruits and vegetables) for 4 weeks
Number of subjects: 92
Study 25218879 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 92
Study 23305152 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised person-centred intervention (WHELD)
Number of subjects: 16
Study 23305152 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 16
Study 22014267 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel containing niosomes loaded with semi-purified fraction containing gallic acid from T. chebula galls (SN)
Number of subjects: 0
Study 22014267 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel containing niosomes loaded with semi-purified fraction containing gallic acid from T. chebula galls (SE)
Number of subjects: 0
Study 22014267 — intervention group
Group type: COMPARATOR
Intervention: Gel containing unloaded fraction (SS)
Number of subjects: 0
Study 22014267 — intervention group
Group type: COMPARATOR
Intervention: Unloaded gallic acid (GS)
Number of subjects: 0
Study 22014267 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel containing gallic acid loaded in non-elastic niosomes (GN)
Number of subjects: 0
Study 22014267 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel containing gallic acid loaded in elastic niosomes (GE)
Number of subjects: 0
Study 22014267 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel containing niosomes loaded with semi-purified fraction containing gallic acid from T. chebula galls (SN and SE)
Number of subjects: 0
Study 19148479 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 236
Study 19148479 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 236
Study 16944236 — intervention group
Group type: EXPERIMENTAL
Intervention: Autofluorescence imaging by spectroscopy using filtered blue light (375‐440 nm)
Number of subjects: 42
Study 16944236 — intervention group
Group type: EXPERIMENTAL
Intervention: Autofluorescence imaging by spectroscopy
Number of subjects: 42
Study 15614997 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported-weight treadmill ambulation training
Number of subjects: 9
Study 15614997 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects performing the same maneuver
Number of subjects: 9
Study 11000320 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioadhesive fluoride tablets (0.5 mg F) used for 5 days
Number of subjects: 8
Study 11000320 — intervention group
Group type: COMPARATOR
Intervention: Control (no fluoride supplements) for 5 days
Number of subjects: 8
Study 9181202 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician advice and nurse-assisted intervention
Number of subjects: 1978
Study 1395766 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dipyridamole (up to 0.84 mg/kg in 10 min)
Number of subjects: 28
Study 1395766 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dipyridamole (300 mg of pulverized tablets)
Number of subjects: 28
Study 1395766 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dipyridamole
Number of subjects: 28
Study 1395766 — intervention group
Group type: COMPARATOR
Intervention: Oral dipyridamole
Number of subjects: 28
Study 3901172 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (300 mg daily)
Number of subjects: 100
Study 3901172 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (600 mg daily)
Number of subjects: 100
Study 3901172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31393548 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus Bevacizumab
Number of subjects: 88
Study 31393548 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib alone
Number of subjects: 88
Study 29665829 — intervention group
Group type: EXPERIMENTAL
Intervention: HeLP-her program (one group session, monthly SMS text messages, one phone coaching session, and a program manual)
Number of subjects: 649
Study 29665829 — intervention group
Group type: EXPERIMENTAL
Intervention: HeLP-her program (for women with BMI ≥ 25 kg/m2)
Number of subjects: 649
Study 29665829 — intervention group
Group type: COMPARATOR
Intervention: General women's health education session (control)
Number of subjects: 649
Study 26903172 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expectations regarding aging
Number of subjects: 0
Study 25492049 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 39
Study 25492049 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 39
Study 22721642 — intervention group
Group type: EXPERIMENTAL
Intervention: LSM+miglitol (50 mg × 3)
Number of subjects: 111
Study 22721642 — intervention group
Group type: COMPARATOR
Intervention: LSM
Number of subjects: 111
Study 21992852 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine plus alemtuzumab (n=168)
Number of subjects: 335
Study 21992852 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine plus alemtuzumab (n=164)
Number of subjects: 335
Study 21992852 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine alone (n=165)
Number of subjects: 335
Study 21992852 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine plus alemtuzumab (n=158)
Number of subjects: 335
Study 21992852 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine plus alemtuzumab (n=157)
Number of subjects: 335
Study 21992852 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine plus alemtuzumab (n=163)
Number of subjects: 335
Study 18504332 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey on knowledge about ACS symptoms and treatment
Number of subjects: 3522
Study 18504332 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher knowledge scores
Number of subjects: 3522
Study 18504332 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived risk for future AMI
Number of subjects: 3522
Study 18504332 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery
Number of subjects: 3522
Study 17136007 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated blood products (40 Gy)
Number of subjects: 20
Study 17136007 — intervention group
Group type: COMPARATOR
Intervention: Non-irradiated blood products
Number of subjects: 20
Study 14510909 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 21
Study 14510909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 10751266 — intervention group
Group type: COMPARATOR
Intervention: CSF tau
Number of subjects: 35
Study 10751266 — intervention group
Group type: COMPARATOR
Intervention: AD7C‐NTP
Number of subjects: 35
Study 10751266 — intervention group
Group type: COMPARATOR
Intervention: Combined evaluation of tau and AD7C‐NTP
Number of subjects: 35
Study 10751266 — intervention group
Group type: COMPARATOR
Intervention: tau
Number of subjects: 35
Study 9223837 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol 2.5 mg twice daily (90%) or 2.5 mg once daily (10%)
Number of subjects: 94
Study 9223837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 9223837 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol
Number of subjects: 94
Study 8310765 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule A (0-1-2-12 months)
Number of subjects: 200
Study 8310765 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule B (0-1-6 months)
Number of subjects: 200
Study 3526773 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ampicillin, mecillinam and metronidazole (group I)
Number of subjects: 168
Study 3526773 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (group II)
Number of subjects: 168
Study 30526573 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face EBM training
Number of subjects: 151
Study 30526573 — intervention group
Group type: EXPERIMENTAL
Intervention: Community management of hypertension (Face-to-face EBM training)
Number of subjects: 151
Study 27909310 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% serum eye drops for PED
Number of subjects: 109
Study 27909310 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatments (historical control)
Number of subjects: 109
Study 24610862 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 25 mg once-daily
Number of subjects: 0
Study 24610862 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg once-daily
Number of subjects: 0
Study 24610862 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (both doses)
Number of subjects: 0
Study 24610862 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine (control)
Number of subjects: 0
Study 23782969 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous catheters
Number of subjects: 263
Study 23782969 — intervention group
Group type: COMPARATOR
Intervention: Peripheral venous catheters
Number of subjects: 263
Study 23782969 — intervention group
Group type: COMPARATOR
Intervention: Peripheral venous catheters only
Number of subjects: 263
Study 23782969 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral and central venous catheters
Number of subjects: 263
Study 19477145 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 12
Study 19477145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19477145 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 12
Study 18822498 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine against Haemophilus influenzae type b administered simultaneously with diphtheria-tetanus-whole cell pertussis and inactivated polio vaccines (Imovax Polio)
Number of subjects: 0
Study 18822498 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine against Haemophilus influenzae type b
Number of subjects: 0
Study 16912120 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 25, 50, 125, 300, or 600 mg weekly for 5 months
Number of subjects: 121
Study 16912120 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 125, 300, and 600 mg
Number of subjects: 121
Study 16912120 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE)
Number of subjects: 121
Study 12522515 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 or 400 mg/d
Number of subjects: 3258
Study 12522515 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 to 400 mg/d
Number of subjects: 3258
Study 12522515 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/d
Number of subjects: 3258
Study 12522515 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg/d
Number of subjects: 3258
Study 12522515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3258
Study 11144049 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 32
Study 11144049 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma patients
Number of subjects: 32
Study 11144049 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 8578831 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4 x 10(3) c.f.u. S. flexneri 2a
Number of subjects: 23
Study 8578831 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4 x 10(2) c.f.u. S. flexneri 2a
Number of subjects: 23
Study 2527130 — intervention group
Group type: EXPERIMENTAL
Intervention: Human ultralente insulin
Number of subjects: 66
Study 2527130 — intervention group
Group type: COMPARATOR
Intervention: Human lente insulin
Number of subjects: 66
Study 336079 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral retinal ablation using the argon laser
Number of subjects: 94
Study 336079 — intervention group
Group type: COMPARATOR
Intervention: Untreated eyes
Number of subjects: 94
Study 31414884 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonized templates after quality improvement initiative
Number of subjects: 19687
Study 31414884 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiologist adherence to harmonized templates
Number of subjects: 19687
Study 29059273 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasquinimod (0.25-1.0 mg/day orally)
Number of subjects: 144
Study 29059273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 29059273 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Number of subjects: 144
Study 26525022 — intervention group
Group type: EXPERIMENTAL
Intervention: Butylphthalide
Number of subjects: 120
Study 26525022 — intervention group
Group type: EXPERIMENTAL
Intervention: Xue Shuan Tong
Number of subjects: 120
Study 26525022 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study 26525022 — intervention group
Group type: EXPERIMENTAL
Intervention: Butylphthalide and Xue Shuan Tong
Number of subjects: 120
Study 23945520 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 cc mDHACM
Number of subjects: 45
Study 23945520 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 cc mDHACM
Number of subjects: 45
Study 23945520 — intervention group
Group type: COMPARATOR
Intervention: Control (1.25 cc saline)
Number of subjects: 45
Study 20859637 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% IAT
Number of subjects: 25
Study 20859637 — intervention group
Group type: COMPARATOR
Intervention: 80% IAT
Number of subjects: 25
Study 17892885 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and ritual prevention (EX/RP)
Number of subjects: 122
Study 17892885 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (CMI)
Number of subjects: 122
Study 17892885 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EX/RP and CMI (EX/RP&CMI)
Number of subjects: 122
Study 17892885 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 122
Study 16996868 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR
Number of subjects: 16176
Study 16996868 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 16176
Study 16996868 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR with trandolapril
Number of subjects: 16176
Study 16996868 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol with hydrochlorothiazide
Number of subjects: 16176
Study 14622688 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (10 mg x kg(‐1) body weight)
Number of subjects: 16
Study 14622688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11049949 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 40
Study 11049949 — intervention group
Group type: COMPARATOR
Intervention: 0.12% unoprostone
Number of subjects: 40
Study 9083230 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 30
Study 9083230 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine-Dobutamine
Number of subjects: 30
Study 8460916 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin (400 mg orally every 12 h)
Number of subjects: 119
Study 8460916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 3539462 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 9
Study 3539462 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine insulin
Number of subjects: 9